For a better experience, Read this story in our App
TO ENJOY ADDITIONAL BENEFITS
Connect With Us
Get BusinessLine apps on
Biotechnology firm Biocon Ltd on Thursday said its board has approved the acquisition of optionally convertible debentures of its arm Biocon Biologics Ltd from Goldman Sachs for $198.5 million.
The board of directors, at its meeting held on June 26, 2025, approved the acquisition of optionally convertible debentures (OCDs) of Biocon Biologics Ltd, an unlisted subsidiary, from Goldman Sachs India Alternative Investment Trust AIF Scheme 2 and Goldman Sachs India AIF Scheme-1 (Goldman Sachs), Biocon Ltd said in a regulatory filing.
The parties have entered into an agreement under which Biocon will "purchase 1,125 unlisted, unsecured, redeemable, optionally convertible debentures (OCDs) of Biocon Biologics of the face value of ₹1 crore each for a consideration of rupee equivalent to $198.5 million, which may be varied depending on the date of purchase," it added.
Under the agreement, the company will acquire 1,047 OCDs from Goldman Sachs India Alternative Investment Trust AIF Scheme 2 and 78 OCDs from Goldman Sachs India AIF Scheme-1, it added.
Published on June 27, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.